Specialty Overview

Best Hospitals for Alpha-1-Antitrypsin Deficiency in Chennai, India

8 liver transplant & hpb hospitals in our India network are listed in Chennai, accredited by JCI, NABH, NABL, with 4,035 beds combined.

8
Hospitals Listed
1
City
4.5
Avg. Rating
3
Accreditation Types
The Short Answer

This page lists the liver transplant & hpb hospitals in our directory offering Alpha-1-Antitrypsin Deficiency in Chennai, India, including Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital and others. Each listing links through to the hospital's full profile page.

Ask us about alpha-1-antitrypsin deficiency in Chennai, India

Share a few details and our care coordination team will get back to you with next steps.

Top Hospitals for Alpha-1-Antitrypsin Deficiency in Chennai, India

🇮🇳 Apollo Hospitals, Greams Road

Chennai, India 4.7 (125 reviews) 560 beds
Why consider this hospital?
4.7/5 rating from 125 reviews560 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by Apollo Hospitals, Greams Road's care team in Chennai, India, from initial consultation through recovery. Apollo Hospitals, Greams Road, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.7/5
Rating
1983
Established
560
Beds
Chennai, India
Location
Gleneagles Global Hospital

🇮🇳 Gleneagles Global Hospital

Chennai, India 4.7 (112 reviews) 1,000 beds
Why consider this hospital?
4.7/5 rating from 112 reviews1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by Gleneagles Global Hospital's care team in Chennai, India, from initial consultation through recovery. Gleneagles Global Hospital, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.7/5
Rating
1999
Established
1,000
Beds
Chennai, India
Location
Dr. Rela Institute and Medical Centre

🇮🇳 Dr. Rela Institute and Medical Centre

Chennai, India 4.7 (108 reviews) 450 beds
Why consider this hospital?
4.7/5 rating from 108 reviews450 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationNABLNational Accreditation Board for Testing and Calibration Laboratories accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by Dr. Rela Institute and Medical Centre's care team in Chennai, India, from initial consultation through recovery. Dr. Rela Institute and Medical Centre, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.7/5
Rating
2018
Established
450
Beds
Chennai, India
Location
SIMS Hospital

🇮🇳 SIMS Hospital

Chennai, India 4.6 (20 reviews) 345 beds
Why consider this hospital?
4.6/5 rating from 20 reviews345 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantOrthopedicsGastroenterology
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by SIMS Hospital's care team in Chennai, India, from initial consultation through recovery. SIMS Hospital, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.6/5
Rating
1970
Established
345
Beds
Chennai, India
Location
Sankara Nethralaya

🇮🇳 Sankara Nethralaya

Nungambakkam, Chennai, India 4.4 (220 reviews) 200 beds
Why consider this hospital?
4.4/5 rating from 220 reviews200 beds
Specialties & Accreditation
OphthalmologyRetina SurgeryCornea TransplantGlaucomaPediatric Ophthalmology
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationNABLNational Accreditation Board for Testing and Calibration Laboratories accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by Sankara Nethralaya's care team in Nungambakkam, Chennai, India, from initial consultation through recovery. Sankara Nethralaya, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.4/5
Rating
1978
Established
200
Beds
Nungambakkam, Chennai, India
Location
Apollo First Med Hospitals, Kilpauk

🇮🇳 Apollo First Med Hospitals, Kilpauk

Kilpauk, Chennai, India 4.4 (76 reviews) 80 beds
Why consider this hospital?
4.4/5 rating from 76 reviews80 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsNeurologyOncologyGastroenterology
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by Apollo First Med Hospitals, Kilpauk's care team in Kilpauk, Chennai, India, from initial consultation through recovery. Apollo First Med Hospitals, Kilpauk, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.4/5
Rating
2002
Established
80
Beds
Kilpauk, Chennai, India
Location
MIOT International

🇮🇳 MIOT International

Manapakkam, Chennai, India 4.4 (200 reviews) 1,000 beds
Why consider this hospital?
4.4/5 rating from 200 reviews1,000 beds
Specialties & Accreditation
OrthopedicsCardiac SurgeryNeurosciencesTransplantOncology
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationNABLNational Accreditation Board for Testing and Calibration Laboratories accreditationJCIJoint Commission International accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by MIOT International's care team in Manapakkam, Chennai, India, from initial consultation through recovery. MIOT International, accredited by NABH, NABL, JCI, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

4.4/5
Rating
1999
Established
1,000
Beds
Manapakkam, Chennai, India
Location
MGM Healthcare

🇮🇳 MGM Healthcare

Chennai, India 3.7 (34 reviews) 400 beds
Why consider this hospital?
3.7/5 rating from 34 reviews400 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantCancer CareOrthopedics
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering alpha-1-antitrypsin deficiency can be cared for by MGM Healthcare's care team in Chennai, India, from initial consultation through recovery. MGM Healthcare, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing alpha-1-antitrypsin deficiency.

3.7/5
Rating
1970
Established
400
Beds
Chennai, India
Location

Top Liver Transplant & HPB Doctors in Chennai, India

Image not available Featured

Dr. Arul Kumar S

MBBS, MS in General Surgery, Fellowship in HPB Surgery, Fellowship in Liver Transplantation
Associate Consultant — Surgical Gastroenterology · Specialty: Hepato-Pancreato-Biliary (HPB) Surgeon
Rela Hospital Chennai, India18+ Years experience
Why consider this doctor?
  • 18+ years of experience in Hepato-Pancreato-Biliary (HPB) Surgeon
  • Associate Consultant, Department of Surgical Gastroenterology and HPB Surgery, Rela Hospital, Chennai
  • Training in HPB Surgery, Christian Medical College, Vellore
Expertise & Procedures
  • Live donor liver transplantation
  • Deceased donor liver transplant
  • Hilar cholangiocarcinoma resection
  • Whipple procedure (pancreaticoduodenectomy)
  • Complex liver resections
View all procedures →
Hepato-Pancreato-Biliary (HPB) Surgeon Experience: 18+ YearsHospital Affiliation: Rela HospitalHospital accreditation: NABH, NABL
Image not available

Dr. Dinesh Jothimani

MBBS, MRCP (UK), CCT in Hepatology, Gastroenterology & General Medicine, FRCP (Glasgow)
Director — Hepatology, Gastroenterology & Hepatobiliary · Specialty: Hepatologist
Dr. Rela Institute & Medical Centre Chennai, India19+ Years experience
Why consider this doctor?
  • 19+ years of experience in Hepatologist
  • Director, Hepatology, Gastroenterology & Hepatobiliary — Dr. Rela Institute & Medical Centre, Chennai
  • Consultant Hepatologist and Liver Transplant Physician — Global Hospitals, Chennai
Expertise & Procedures
  • ERCP (Endoscopic Retrograde Cholangiopancreatography)
  • Liver Transplant Assessment and Management
  • Hepatic Biopsy and Fibroscan
  • Endoscopic Variceal Ligation
  • Management of Acute Liver Failure
View all procedures →
Hepatologist Experience: 19+ YearsHospital Affiliation: Dr. Rela Institute & Medical CentreHospital accreditation: NABH, NABL
Image not available

Dr. Gomathy Narasimhan

MBBS, MS, ASTS Fellowship in Transplant Surgery, GMHE
Senior Consultant — Liver and Renal Transplant Surgery & Surgical Gastroenterology · Specialty: Liver Transplant Surgeon
Rela Hospital Chennai, India20+ Years experience
Why consider this doctor?
  • 20+ years of experience in Liver Transplant Surgeon
  • Senior Consultant — Liver and Renal Transplant Surgery & Surgical Gastroenterology, Rela Hospital, Chennai, Present
  • ASTS Fellowship in Transplant Surgery, Baylor University Medical Center, Dallas, Texas, USA, 2006
Expertise & Procedures
  • Adult liver transplantation
  • Pediatric liver transplant
  • Living donor kidney transplant
  • Combined liver-kidney transplant
  • Multivisceral transplant
View all procedures →
Liver Transplant Surgeon Experience: 20+ YearsHospital Affiliation: Rela HospitalHospital accreditation: NABH, NABL
Image not available

Dr. Jasper Sandeep Rajasekar

MBBS, MS, MCh, MRCS
Associate Consultant — Surgical Gastroenterology · Specialty: Hepatobiliary & Liver Transplant Surgeon
Rela Hospital Chennai, India11+ Years experience
Why consider this doctor?
  • 11+ years of experience in Hepatobiliary & Liver Transplant Surgeon
  • Associate Consultant, Surgical Gastroenterology, Rela Hospital, Chennai — Present
  • Liver Transplantation Unit Member, Rela Hospital, Chennai — 2016–Present
Expertise & Procedures
  • Living donor liver transplantation (LDLT)
  • Deceased donor liver transplantation
  • Pediatric liver transplantation
  • Hepatocellular carcinoma resection
  • Whipple procedure (pancreaticoduodenectomy)
View all procedures →
Hepatobiliary & Liver Transplant Surgeon Experience: 11+ YearsHospital Affiliation: Rela HospitalHospital accreditation: NABH, NABL
Image not available

Dr. Joy Varghese

MBBS, MD, DM (Gastroenterology), PhD, Fellowship in Liver Transplantation
Director of Hepatology & Transplant Hepatology — Gastroenterology & Hepatobiliary · Specialty: Hepatologist & Liver Transplant Physician
Gleneagles HealthCity Chennai Chennai, India25+ Years experience
Why consider this doctor?
  • 25+ years of experience in Hepatologist & Liver Transplant Physician
  • Director of Hepatology & Transplant Hepatology – Gleneagles HealthCity, Chennai, India – Present
  • Program Director, Liver Transplant Society of India (LTSI) Fellowship in Transplant Hepatology – Gleneagles HealthCity, Chennai – Present
Expertise & Procedures
  • Orthotopic Liver Transplantation
  • Living Donor Liver Transplantation
  • Liver Biopsy
  • Endoscopic Variceal Ligation
  • Therapeutic Plasma Exchange for Liver Diseases
View all procedures →
Hepatologist & Liver Transplant Physician Experience: 25+ YearsHospital Affiliation: Gleneagles HealthCity ChennaiHospital accreditation: NABH, JCI
Image not available

Dr. Kumar Palaniappan

MBBS, DNB General Surgery, DNB Surgical Gastroenterology, Fellowship in Liver Transplantation & HPB Surgery
Clinical Lead — Laparoscopy Liver Surgery, Surgical Gastroenterology · Specialty: Hepatobiliary & Liver Transplant Surgeon
Rela Hospital Chennai, India20+ Years experience
Why consider this doctor?
  • 20+ years of experience in Hepatobiliary & Liver Transplant Surgeon
  • Clinical Lead – Laparoscopy Liver Surgery, Senior Consultant Abdominal Trauma, HPB Surgery & Liver Transplantation, Rela Hospital, Chennai – Present
  • Senior Consultant Hepatobiliary & Liver Transplant Surgery, Gleneagles Global Hospitals, Chennai
Expertise & Procedures
  • Liver Transplantation (Living & Deceased Donor)
  • Laparoscopic Liver Resection
  • Hepatic Tumor Surgery
  • Whipple Procedure (Pancreaticoduodenectomy)
  • Gastrectomy
View all procedures →
Hepatobiliary & Liver Transplant Surgeon Experience: 20+ YearsHospital Affiliation: Rela HospitalHospital accreditation: NABH, NABL
Our Methodology

How we selected these hospitals

A hospital appears on this page when Liver Transplant & HPB is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Alpha-1-Antitrypsin Deficiency in Chennai, India?

Choosing the right hospital for alpha-1-antitrypsin deficiency is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include liver transplant & hpb rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Alpha-1-Antitrypsin Deficiency

Alpha-1-Antitrypsin Deficiency (AATD) is a serious inherited metabolic disorder that leads to progressive emphysema and liver disease; AAT augmentation therapy (intravenous infusion of purified human alpha-1-antitrypsin) is the only disease-modifying treatment proven to slow lung function decline in Pi*ZZ and related phenotypes, with clinical studies demonstrating a statistically significant reduction in CT-measured lung density loss and annual FEV1 decline.

1–2 days per infusion cycle (outpatient or short-stay); 5–10 days for initial diagnostic work-up and therapy induction if travelling internationally
Hospital Stay
1–2 weeks for initial evaluation, therapy initiation, and tolerance monitoring before international travel home; ongoing therapy requires return visits every 4–8 weeks or coordination with a home infusion provider
Total Stay in Country (Fit-to-Fly)
Augmentation therapy reduces annual CT lung density decline by approximately 34% compared to placebo (RAPID trial data); liver-directed therapies (RNA interference, gene therapy trials) show 80–95% target engagement in early-phase studies. Overall treatment response (stabilisation of lung function trajectory) is documented in 70–85% of compliant patients.
Success Rate

Clinical Overview

  • Alpha-1-Antitrypsin Deficiency (AATD) is an autosomal co-dominant genetic disorder caused by mutations in the SERPINA1 gene, most commonly the Pi*Z (Glu342Lys) allele.
  • The resulting misfolded AAT protein is retained within hepatic endoplasmic reticulum, reducing circulating AAT to less than 11 µmol/L — far below the protective threshold of 35 µmol/L needed to neutralise neutrophil elastase in alveolar tissue.
  • The unopposed elastase activity progressively destroys alveolar walls, producing panlobular emphysema with a characteristic basal predominance on high-resolution CT (HRCT).
Full details →

Who is a Candidate?

  • CONFIRMED PHENOTYPE: Pi*ZZ, Pi*ZNull, Pi*SZ, or other severe AATD genotypes confirmed by serum AAT level (< 11 µmol/L or < 57 mg/dL by nephelometry) AND SERPINA1 genotyping or isoelectric focusing (IEF)
  • PULMONARY ELIGIBILITY FOR AUGMENTATION: FEV1 15–65% predicted on spirometry; CT-documented emphysema (quantitative PD15 densitometry); non-smoker or smoking cessation confirmed ≥ 6 months; absence of IgA deficiency (risk of anaphylaxis to plasma products)
  • LIVER DISEASE EVALUATION: All AATD patients require baseline liver assessment — serum LFTs, FibroScan® (liver stiffness ≥ 7 kPa warrants enhanced surveillance), abdominal ultrasound, and AFP for HCC screening in cirrhotic patients
  • REQUIRED PRE-TREATMENT DIAGNOSTICS: Full pulmonary function tests (spirometry, body plethysmography, DLCO); HRCT thorax with quantitative densitometry; 6-minute walk test (6MWT) and SGRQ-C quality-of-life score; echocardiography (ECHO) to exclude pulmonary hypertension (RVSP > 40 mmHg modifies transplant candidacy); complete blood count, coagulation profile, serum protein electrophoresis; hepatitis B/C serology and HIV screening
  • +4 more

Treatment Options & Approaches

  • STANDARD AAT AUGMENTATION THERAPY (INTRAVENOUS): Weekly IV infusion of purified, pasteurised, human plasma-derived alpha-1-antitrypsin concentrate at 60 mg/kg body weight, administered over 15–30 minutes in an outpatient or day-care setting.
  • This is the only FDA-approved, EMA-approved disease-modifying therapy for AATD-related emphysema.
  • The RAPID and RAPID-OLE trials (the only double-blind, placebo-controlled studies in AATD) demonstrated a 34% reduction in annual CT lung density loss (PD15 endpoint) and a significant benefit in FEV1 decline in the treatment arm over 4 years.

Recovery

  • PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel):

Risks to be aware of

  • AAT augmentation therapy has an established safety profile across three decades of clinical use, but patients and clinicians must consider the following specific risks and limitations:
Full details →

Why GAF Healthcare

  • GAF Healthcare provides a fully integrated non-medical support infrastructure designed to eliminate barriers to international treatment access for AATD patients:

Common questions about Alpha-1-Antitrypsin Deficiency

What is the cost of Alpha-1-Antitrypsin Deficiency Treatment (AAT Augmentation Therapy) in India versus the UAE?
An initial international treatment visit to India — covering comprehensive AATD diagnostic confirmation (spirometry, quantitative HRCT, FibroScan®, SERPINA1 genotyping, full blood panel), MDT consultations, and initiation of AAT augmentation therapy (2 supervised infusions) — costs approximately USD 2,500 to USD 6,000 at JCI- and NABH-accredited hospitals in Mumbai, Delhi, or Chennai. Equivalent treatment at JCI- and DHA-accredited hospitals in Dubai or Abu Dhabi typically ranges from USD 5,000 to USD 12,000 for the same scope of care. This represents a cost saving of 40–60% in India versus the UAE. It is important to note that AAT augmentation therapy is a lifelong weekly infusion; the cost of ongoing therapy once the patient returns home depends on local pharmaceutical pricing and insurance coverage. For surgical interventions — endobronchial valve lung volume reduction (approximately USD 8,000–15,000 in India vs. USD 18,000–30,000 in UAE) or bilateral lung transplantation (approximately USD 40,000–75,000 in India vs. USD 120,000–200,000 in UAE) — GAF Healthcare provides itemised cost estimates following clinical evaluation. All quoted ranges are inclusive of hospital stay, standard medications, nursing care, and standard investigative procedures.
How long do I need to stay in India or the UAE before I am fit to fly home after starting AAT Augmentation Therapy?
For patients travelling internationally to initiate AAT augmentation therapy, the recommended minimum in-country stay is 10 to 14 days. The first 3 days are dedicated to comprehensive baseline diagnostics and MDT review. Therapy is initiated on Day 4 with the first IV infusion, followed by a second infusion approximately 7 days later. A minimum 60-minute post-infusion observation period is required after each infusion to monitor for hypersensitivity reactions. Flight clearance is issued by the treating pulmonologist once two infusions have been tolerated without adverse events, the patient's SpO2 is ≥ 92% on room air at rest, and no acute pulmonary exacerbation is occurring. Patients with baseline resting SpO2 below 92% must undergo a hypoxia altitude simulation test (HAST) to determine whether in-flight supplemental oxygen (typically 2 L/min via nasal cannula) is required — this adds 1–2 days to the pre-departure timeline. For patients undergoing endobronchial valve (BLVR) procedures, the in-country stay is typically 7–10 days post-procedure given the 10–14% pneumothorax risk in the first 72 hours. Lung or liver transplant recipients require a minimum 4–8 weeks in-country post-surgery before international travel clearance.
What is the success rate of AAT Augmentation Therapy and related AATD treatments?
Success rates vary by treatment modality and the outcome measure used. For AAT augmentation therapy, the landmark RAPID and RAPID-OLE double-blind placebo-controlled trials demonstrated a 34% reduction in annual CT lung density loss (PD15 endpoint) compared to placebo over 2–4 years — the most objective and validated measure of disease-modifying efficacy in AATD emphysema. Augmentation therapy stabilises lung function trajectory in approximately 70–85% of compliant patients, with the greatest benefit seen in those with FEV1 between 35–65% predicted. The therapy does not reverse existing emphysema but significantly slows progression. For endobronchial lung volume reduction (Zephyr valves), the LIBERATE trial demonstrated a mean FEV1 improvement of 14.6% above placebo at 12 months, with 47% of treated patients achieving a clinically meaningful response (MCID ≥ 15% FEV1 improvement). For bilateral lung transplantation in AATD, the ISHLT registry reports 1-year survival of 80–85% and 5-year survival of 50–60%, which is among the better outcomes of all COPD indications for transplant. Liver transplantation for AATD-related cirrhosis achieves 1-year graft survival of 85–90% at high-volume centres in India. Emerging RNA interference therapies (fazirsiran) have shown 80–90% reduction in hepatic Z-AAT polymer in Phase 2 trials, with liver fibrosis stabilisation or improvement in the majority of participants. GAF Healthcare partner centres in India and the UAE report outcomes consistent with or superior to published international benchmarks, supported by prospective outcome tracking and participation in the Alpha-1 International Registry (AIR).

How GAF Healthcare Assists in Choosing the Best Hospital for Alpha-1-Antitrypsin Deficiency in Chennai, India

Discover the Top Hospitals for Alpha-1-Antitrypsin Deficiency in Chennai, India

This page lists 8 accredited liver transplant & hpb hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Patient Success Story

Iraqi Family's Journey: Baby Ibrahim's Life-Saving Heart Surgery in India
Common Questions

Frequently asked questions about alpha-1-antitrypsin deficiency in Chennai, India

How many liver transplant & hpb hospitals are listed in Chennai, India?
8 hospitals in our Chennai, India directory are currently listed for liver transplant & hpb including Alpha-1-Antitrypsin Deficiency.
How do you choose which hospitals to list?
A hospital appears on this page when Liver Transplant & HPB is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there liver transplant & hpb hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for alpha-1-antitrypsin deficiency?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about alpha-1-antitrypsin deficiency in Chennai, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for alpha-1-antitrypsin deficiency in Chennai, India.

Contact us to report an inaccuracy on this page.